Sinocelltech Group Ltd (688520) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinocelltech Group Ltd (688520) has a cash flow conversion efficiency ratio of 0.137x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-100.18 Million ≈ $-14.66 Million USD) by net assets (CN¥-730.66 Million ≈ $-106.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sinocelltech Group Ltd (688520) net asset quality to measure how much of total assets are equity-financed.
Sinocelltech Group Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sinocelltech Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 688520 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Sinocelltech Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinocelltech Group Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
UCloud Technology Co Ltd
SHG:688158
|
0.024x |
|
United Natural Foods Inc
NYSE:UNFI
|
-0.025x |
|
Triumph Science & Technology Co Ltd
SHG:600552
|
-0.015x |
|
Gudang Garam Tbk
JK:GGRM
|
0.037x |
|
Rogers Corporation
NYSE:ROG
|
0.005x |
|
Ruentex Development Co Ltd
TW:9945
|
0.017x |
|
Zhejiang Publishing & Media Co Ltd
SHG:601921
|
-0.028x |
|
China Railway Hi-tech Industry Corp Ltd
SHG:600528
|
0.101x |
Annual Cash Flow Conversion Efficiency for Sinocelltech Group Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sinocelltech Group Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Sinocelltech Group Ltd (688520) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥134.94 Million ≈ $19.75 Million |
CN¥125.12 Million ≈ $18.31 Million |
0.927x | +47.52% |
| 2023-12-31 | CN¥-605.81 Million ≈ $-88.65 Million |
CN¥-380.80 Million ≈ $-55.72 Million |
0.629x | -64.42% |
| 2022-12-31 | CN¥-242.19 Million ≈ $-35.44 Million |
CN¥-427.91 Million ≈ $-62.62 Million |
1.767x | -52.70% |
| 2021-12-31 | CN¥-230.99 Million ≈ $-33.80 Million |
CN¥-862.82 Million ≈ $-126.26 Million |
3.735x | +508.95% |
| 2020-12-31 | CN¥588.36 Million ≈ $86.10 Million |
CN¥-537.41 Million ≈ $-78.64 Million |
-0.913x | +93.45% |
| 2019-12-31 | CN¥34.80 Million ≈ $5.09 Million |
CN¥-485.10 Million ≈ $-70.99 Million |
-13.938x | -477.54% |
| 2018-12-31 | CN¥-23.84 Million ≈ $-3.49 Million |
CN¥-88.02 Million ≈ $-12.88 Million |
3.692x | +764.28% |
| 2017-12-31 | CN¥167.84 Million ≈ $24.56 Million |
CN¥-93.28 Million ≈ $-13.65 Million |
-0.556x | -10.91% |
| 2016-12-31 | CN¥80.38 Million ≈ $11.76 Million |
CN¥-40.28 Million ≈ $-5.89 Million |
-0.501x | -- |
About Sinocelltech Group Ltd
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more